Epoprostenol (Flolan, Veletri)

Epoprostenol (Flolan, Veletri) is covered only for FDA‑approved pulmonary arterial hypertension (WHO Group 1) and compendial off‑label chronic thromboembolic pulmonary hypertension (CTEPH) and is not supported for other indications. Coverage requires PAH confirmation by right‑heart catheterization, prescription/consultation by a pulmonologist or cardiologist, NYHA class III/IV (or class II with prior/ongoing oral or inhaled/parenteral prostacyclin therapy or specified vasodilator/CCB criteria for idiopathic PAH), adherence to dosing limits (≤100 ng/kg/min IV for PAH; ≤45 ng/kg/min IV for CTEPH), 12‑month approvals with documentation of continued benefit for renewals, and a single short‑term 30‑day exception when criteria or information are insufficient.

"Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity."